---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-26-000055"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2026-10-23T10:07:04+00:00"
generated_at: "2026-10-23T10:10:04.181144+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zymeworks licenses DLL3 T-cell engager ZW209 to Roche for $55M upfront, up to $758M in milestones

## Summary
- Roche pays $55M upfront after HSR clearance, plus a $40M milestone on the first ZW209 Phase 1b trial; up to $718M in development, commercial and sales milestones.
- Zymeworks also gets tiered high-single-digit to mid-teen royalties on global net sales, payable until the later of 10 years post-launch or patent expiry (patents into the 2040s).
- Zymeworks runs the Phase 1a monotherapy trial at Roche's expense; Roche funds it and takes over all later global development, manufacturing and commercialization.
- Exclusive worldwide license covers ZW209 and other DLL3 trispecific T-cell engagers; Zymeworks is barred from DLL3 T-cell engager work for up to 5 years or first Phase 3 start.
- FDA IND clearance for ZW209 received; deal still subject to HSR waiting period; investor call October 27 at 8:30 am ET.

## SEC filing metadata
- accession: 0001937653-26-000055
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2026-10-23T10:07:04+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/0001937653-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/zyme-20261022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-26-000055
- JSON: https://secwatch.observer/filing/0001937653-26-000055.json
- Plain text: https://secwatch.observer/filing/0001937653-26-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
